Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin, Venetoclax, and Rituximab/Hyaluronidase in R/R MCL
NCT04659044Phase 2Terminated
- Sponsor
- Academic and Community Cancer Research United
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in mantle cell lymphoma (MCL), sponsored by Academic and Community Cancer Research United. Started Apr 2021; status: terminated.
02
Drugs
polatuzumab vedotin
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04659044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659044.